BR112012019866A8 - Composto, uso do mesmo, composição farmacêutica, e, processo para preparar um composto - Google Patents
Composto, uso do mesmo, composição farmacêutica, e, processo para preparar um compostoInfo
- Publication number
- BR112012019866A8 BR112012019866A8 BR112012019866A BR112012019866A BR112012019866A8 BR 112012019866 A8 BR112012019866 A8 BR 112012019866A8 BR 112012019866 A BR112012019866 A BR 112012019866A BR 112012019866 A BR112012019866 A BR 112012019866A BR 112012019866 A8 BR112012019866 A8 BR 112012019866A8
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- preparing
- pharmaceutical composition
- compounds
- useful
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000134 cyclophilin inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Biotechnology (AREA)
- Psychology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1002097.2A GB201002097D0 (en) | 2010-02-09 | 2010-02-09 | Novel compounds |
| GBGB1006128.1A GB201006128D0 (en) | 2010-04-13 | 2010-04-13 | Novel compounds |
| GBGB1101085.7A GB201101085D0 (en) | 2011-01-21 | 2011-01-21 | Novel compounds |
| PCT/GB2011/050236 WO2011098809A1 (en) | 2010-02-09 | 2011-02-09 | Sanglifehrin based compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112012019866A2 BR112012019866A2 (pt) | 2017-07-11 |
| BR112012019866A8 true BR112012019866A8 (pt) | 2017-12-26 |
Family
ID=43836693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012019866A BR112012019866A8 (pt) | 2010-02-09 | 2011-02-09 | Composto, uso do mesmo, composição farmacêutica, e, processo para preparar um composto |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9119853B2 (https=) |
| EP (1) | EP2533784B1 (https=) |
| JP (1) | JP5894935B2 (https=) |
| AU (1) | AU2011214135B2 (https=) |
| BR (1) | BR112012019866A8 (https=) |
| CA (1) | CA2788761C (https=) |
| ES (1) | ES2541853T3 (https=) |
| MX (1) | MX2012008873A (https=) |
| WO (1) | WO2011098809A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201008123D0 (en) * | 2010-05-17 | 2010-06-30 | Biotica Tech Ltd | Novel compounds |
| JO3063B1 (ar) * | 2011-03-29 | 2017-03-15 | Neurovive Pharmaceutical Ab | مركب مبتكر وطرق لانتاجه |
| GB201118334D0 (en) * | 2011-10-24 | 2011-12-07 | Biotica Tech Ltd | Novel dosage form |
| WO2018091634A1 (en) | 2016-11-18 | 2018-05-24 | Neurovive Pharmaceutical Ab | Use of sanglifehrin macrocyclic analogues as anticancer compounds |
| KR20210116479A (ko) * | 2018-12-21 | 2021-09-27 | 레볼루션 메디슨즈, 인크. | 공동 결합에 참여하는 화합물 및 그의 용도 |
| MX2022005359A (es) | 2019-11-04 | 2022-06-02 | Revolution Medicines Inc | Inhibidores de ras. |
| MX2023003060A (es) | 2020-09-15 | 2023-04-05 | Revolution Medicines Inc | Derivados indolicos como inhibidores de ras en el tratamiento del cancer. |
| AU2022268962A1 (en) | 2021-05-05 | 2023-12-14 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR006514A1 (es) | 1995-07-04 | 1999-09-08 | Sandoz Ag | Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende |
| US6124453A (en) | 1995-07-04 | 2000-09-26 | Novartis Ag | Macrolides |
| AP1029A (en) | 1996-07-05 | 2001-12-11 | Biotica Tech Limited | Erythromycins and process for their preparation. |
| GB9814622D0 (en) | 1998-07-06 | 1998-09-02 | Biotica Tech Ltd | Polyketides,their preparation,and materials for use therein |
| US20090221598A1 (en) | 2005-06-17 | 2009-09-03 | Kai Lin | Use of Sanglifehrin in HCV |
| CA2674296C (en) | 2007-01-04 | 2015-11-24 | Debiopharm Sa | Non-immunosuppressive cyclosporin for treatment of ullrich congenital muscular dystrophy |
| EP2342335B1 (en) | 2008-09-24 | 2015-09-16 | Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences | Novel gene cluster |
| JO3063B1 (ar) | 2011-03-29 | 2017-03-15 | Neurovive Pharmaceutical Ab | مركب مبتكر وطرق لانتاجه |
-
2011
- 2011-02-09 AU AU2011214135A patent/AU2011214135B2/en not_active Ceased
- 2011-02-09 WO PCT/GB2011/050236 patent/WO2011098809A1/en not_active Ceased
- 2011-02-09 ES ES11704308.3T patent/ES2541853T3/es active Active
- 2011-02-09 BR BR112012019866A patent/BR112012019866A8/pt not_active Application Discontinuation
- 2011-02-09 CA CA2788761A patent/CA2788761C/en not_active Expired - Fee Related
- 2011-02-09 JP JP2012552469A patent/JP5894935B2/ja not_active Expired - Fee Related
- 2011-02-09 US US13/575,212 patent/US9119853B2/en active Active
- 2011-02-09 EP EP20110704308 patent/EP2533784B1/en not_active Not-in-force
- 2011-02-09 MX MX2012008873A patent/MX2012008873A/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| CA2788761A1 (en) | 2011-08-18 |
| WO2011098809A1 (en) | 2011-08-18 |
| CA2788761C (en) | 2018-05-29 |
| JP2013518923A (ja) | 2013-05-23 |
| AU2011214135B2 (en) | 2014-07-31 |
| JP5894935B2 (ja) | 2016-03-30 |
| BR112012019866A2 (pt) | 2017-07-11 |
| US20120295841A1 (en) | 2012-11-22 |
| MX2012008873A (es) | 2012-11-22 |
| AU2011214135A1 (en) | 2012-08-23 |
| CN102770139A (zh) | 2012-11-07 |
| EP2533784A1 (en) | 2012-12-19 |
| EP2533784B1 (en) | 2015-04-22 |
| ES2541853T3 (es) | 2015-07-27 |
| US9119853B2 (en) | 2015-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012019866A8 (pt) | Composto, uso do mesmo, composição farmacêutica, e, processo para preparar um composto | |
| ECSP11011183A (es) | Compuestos orgánicos | |
| ECSP11011184A (es) | Compuestos orgánicos | |
| CO6321282A2 (es) | Derivados de piperidinilindol como inhibidores de aldosterona sintasa | |
| CR20140361A (es) | Inhibidores de pde9 con estructura básica de imidazotriazinona | |
| EA201001205A1 (ru) | Соединения, содержащие циклобутоксигруппу | |
| BR112013031493A2 (pt) | composto, composição farmacêutica, uso de um composto, combinação de um composto, dispositivo e processo de preparação de um composto. | |
| CO6362015A2 (es) | Derivados de acido 1-amino-2ciclobutiletilboronico | |
| CO6620055A2 (es) | Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos | |
| BR112013004662B8 (pt) | Composto, composição farmacêutica, usos de um composto, e método para preparar uma composição farmacêutica | |
| CU20140110A7 (es) | Compuestos heterocíclicos como inhibidores de mek | |
| MX2012014017A (es) | Derivados de heteroaril imidazolona como inhibidores de jak. | |
| CL2008003041A1 (es) | Compuestos derivados de acido boronico, inhibidores de proteasoma; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. | |
| BR112012026767A2 (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratar ou previnir distúrbios, e, uso de um composto ou sal | |
| UY32611A (es) | Compuestos de 1-cianoetilheterociclilcarboxamida sustituidos 750 | |
| ECSP12012318A (es) | Inhibidores de pirazolil quinazolina cinasa | |
| CR20140161A (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
| CR20120334A (es) | Derivados de imidazopiridina como inhibidores de jak | |
| CR20150045A (es) | Inhibidores de hepatitis c | |
| UA111161C2 (uk) | Похідна фталазинонкетону, спосіб її одержання та її фармацевтичне застосування | |
| EA201391313A1 (ru) | C4-монометилтритерпеноидные производные и способы их применения | |
| MY186599A (en) | Substituted pyridopyrazines as novel syk inhibitors | |
| UY31905A (es) | Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones. | |
| BR112012009310A2 (pt) | composto, e, composição farmacêutica | |
| EA201001855A1 (ru) | Соединения, содержащие циклобутоксигруппу |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25G | Requested change of headquarter approved |
Owner name: BIOTICA TECHNOLOGY LIMITED (GB) |
|
| B25A | Requested transfer of rights approved |
Owner name: NEUROVIVE PHARMACEUTICAL AB (SE) |
|
| B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |